Yarrow Bioscience COO reports 175,639-share option
Yarrow Bioscience, Inc. reports that Chief Operating Officer Rachael Alford holds a stock option to purchase 175,639 shares of its common stock at an exercise price of $6.1900 per share, expiring on January 30, 2036.
Rhea-AI Filing Summary
Yarrow Bioscience, Inc. reports that Chief Operating Officer Rachael Alford holds a stock option to purchase 175,639 shares of its common stock at an exercise price of $6.1900 per share, expiring on January 30, 2036. The option was received in the merger in which a wholly owned subsidiary of VYNE Therapeutics Inc. merged with Yarrow Bioscience, after which VYNE changed its name to Yarrow Bioscience, Inc. One quarter of this option will vest on January 26, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to her continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Alford Rachael
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 175,639 contracts (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 175,639 shares of Issuer Common Stock, one quarter of which will vest on January 26, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Underlying shares: 175,639 shares
Exercise price: $6.1900 per share
Option expiration date: 2036-01-30
+3 more
6 metrics
Underlying shares
175,639 shares
Right to purchase Issuer Common Stock under reported stock option
Exercise price
$6.1900 per share
Exercise price of the Stock Option (Right to Buy)
Option expiration date
2036-01-30
Expiration date of the reported stock option
Initial vesting date
January 26, 2027
One quarter of the option vests on this date
Remaining vesting period
three years
Remaining three quarters vest in equal monthly installments after initial vesting
Par value
$0.0001 per share
Par value of Issuer Common Stock underlying the option
Key Terms
Stock Option (Right to Buy), Effective Time, par value, vest
4 terms
Stock Option (Right to Buy) financial
"Security title reported as "Stock Option (Right to Buy)""
Effective Time regulatory
"Effective as of July 27, 2026 (the "Effective Time"), a wholly owned"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
par value financial
"shares of common stock, par value $0.0001, of the Issuer"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
vest financial
"one quarter of which will vest on January 26, 2027, with the remaining"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this Form 3 reveal about Yarrow Bioscience (VYNE/YARW)?
It shows COO Rachael Alford holds a stock option for 175,639 shares of Yarrow Bioscience common stock. The option was assumed and converted in the VYNE–Yarrow merger and keeps the same terms and conditions as her prior Yarrow options.
What is the exercise price and expiration of Rachael Alford’s Yarrow Bioscience option?
The stock option has an exercise price of $6.1900 per share and expires on 2036-01-30. These terms apply to options converted into Yarrow Bioscience, Inc. common stock at the Effective Time of the merger with VYNE’s subsidiary.
How does Rachael Alford’s Yarrow Bioscience stock option vest?
One quarter of the option will vest on January 26, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years. Vesting is conditioned on her continued service to Yarrow Bioscience, Inc. on each vesting date.
How did the VYNE Therapeutics and Yarrow Bioscience merger affect the company name?
At the merger’s Effective Time, a VYNE subsidiary merged into Yarrow, which became a wholly owned subsidiary named Yarrow Bioscience Operating Company Corp. In connection with completion of the merger, VYNE changed its name to "Yarrow Bioscience, Inc.".
Is Rachael Alford’s Yarrow Bioscience option a new grant or a converted award?
It is a converted award. The Form 3 states the option represents Issuer Common Stock options received in exchange for Yarrow options she held before the merger, with each such option assumed and converted on the same terms and conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
